Pyrimidine derivatives, preparation method therefor and application of pyrimidine derivatives

A technology of pyrimidines and derivatives, applied in the field of drug synthesis

Active Publication Date: 2018-02-02
SHENYANG PHARMA UNIVERSITY
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although a series of PAK inhibitors have been disclosed, there is still no PAK inhibitor drug on the market, and it is still necessary to develop compounds with novel structures and better efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pyrimidine derivatives, preparation method therefor and application of pyrimidine derivatives
  • Pyrimidine derivatives, preparation method therefor and application of pyrimidine derivatives
  • Pyrimidine derivatives, preparation method therefor and application of pyrimidine derivatives

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0134] Preparation of A-B Fused Pyrimidine Ring Nucleus

[0135] (Method A)

[0136]

[0137] Preparation of 2,4-dihydroxy-6-chloroquinazoline (M1)

[0138]Mix 2-amino-5-chlorobenzoic acid (15.0g, 0.087mol) with urea (52.3g, 0.87mol), heat to melt and react at 200°C for 3 hours, stop heating, let cool, add 300ml of water, stir and heat to reflux for 1 After 1 hour, it was suction filtered while it was hot, and the solid was dried to obtain 13.77 g of a light yellow solid, with a yield of 80.5%.

[0139] ESI-MS(m / z): 197[M+H] + .

[0140] Preparation of 2,4,6-trichloroquinazoline (M2)

[0141] Add 2,4-dihydroxy-6-chloroquinazoline (M1) (16.0g, 0.081mol) into the reaction flask, add phosphorus oxychloride (47ml, 0.515mol), and add N,N-di Methylaniline (31ml, 0.243mol) was heated and refluxed for 3 hours, stopped heating, allowed to cool and poured into 500ml of ice water, a brownish black solid was precipitated, suction filtered, dried, and column chromatography (petrole...

Embodiment 1

[0183] Example 1: N 4 -(2-(1H-indol-3-yl)ethyl)-N 2 Preparation of -(1H-indazol-5-yl)quinazoline-2,4-diamine

[0184]

[0185] Step A-1 Preparation of N-(2-(1H-indol-3-yl)ethyl)-2-chloroquinazolin-4-amine (1)

[0186] Disperse 1.98g (0.01mol) of 2,4-dichloroquinazoline and 1.76g (0.0011mol) of tryptamine in 50ml of DMF, slowly add 0.32g (0.025mol) of DIEA into the solution under stirring in an ice bath, and drop it in After reacting for 2 hours at a reaction temperature of 0°C, pour it into 300ml of ice water to precipitate a light yellow solid, filter it with suction, and dry it to obtain 2.70 g of a light yellow solid with a yield of 83.4%. ESI-MS (m / z): 323 [M+ H] + .

[0187] Step A-2N 4 -(2-(1H-indol-3-yl)ethyl)-N 2 Preparation of -(1H-indazol-5-yl)quinazoline-2,4-diamine

[0188] Add 0.32 g (0.001 mol) of intermediate (1) and 0.27 g (0.002 mol) of 5-aminoindazole into the sealed tube, add 10 ml of absolute ethanol and 10 uL of hydrochloric acid, react at 120 de...

Embodiment 2

[0190] Example 2: N 4 -(2-(1H-indol-3-yl)ethyl)-N 2 -(1H-Indazol-5-yl)-6-methoxyquinazoline-2,4-diamine

[0191] ESI-MS(m / z): 450[M+H] + .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of drug synthesis and relates to novel pyrimidine derivatives, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, preparation methods of thenovel pyrimidine derivatives and the pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof and use of the novel pyrimidine derivatives and the pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof in preparation of therapeutic agents, particularly PAK inhibitors. The derivatives disclosed by the invention are represented by a general formula (I) or (II), wherein each substituent is as defined in claims.

Description

technical field [0001] The invention belongs to the field of drug synthesis, and relates to a class of novel pyrimidine derivatives, pharmaceutically acceptable salts, hydrates, solvates or prodrugs of the derivatives, their preparation methods and their use in the preparation of therapeutic agents, especially Use in the preparation of PAK inhibitors. Background technique [0002] Protein kinase is currently the largest known protein superfamily. Since the discovery of protein kinase activity in 1954, research in this field has developed rapidly. There are about 538 protein kinases that have been discovered, and their coding genes account for about About 2% of the human genome. As follows: [0003] [0004] Protein kinase catalyzes the transfer of the terminal phosphate group of ATP to a specific amino acid of the substrate in vivo to phosphorylate the substrate. According to the type of amino acid residues phosphorylated in the substrate protein, they can be divided in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(China)
IPC IPC(8): C07D403/14C07D491/048C07D495/04C07D471/04A61K31/517A61K31/519A61P35/00
CPCC07D403/14C07D471/04C07D491/048C07D495/04
Inventor赵冬梅程卯生郝晨洲郭靖宋帅张巧玲王健黄万旭李丰李晓东
OwnerSHENYANG PHARMA UNIVERSITY